Evidence map›Paper›PMID 39578852›Full record

ArticleCell & bioscience2024

Splicing factor SRSF1 attenuates cardiomyocytes apoptosis via regulating alternative splicing of Bcl2L12.

Yilin Xie, Zhenbo Yang, Wenxian Chen, Changsheng Zhong, Mengyang Li, Lei Zhang, Ting Cheng, Qin Deng, Huifang Wang, Jin Ju and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell & bioscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yilin Xie *Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Jinan University, Zhuhai, 519000, Guangdong, China.
Zhenbo Yang *College of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Wenxian ChenCollege of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Changsheng ZhongCollege of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Mengyang LiCollege of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Lei ZhangCollege of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Ting ChengCollege of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Qin DengCollege of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Huifang WangCollege of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Jin JuCollege of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Zhimin DuZhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Jinan University, Zhuhai, 519000, Guangdong, China. dzm1956@126.com.
Haihai LiangZhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Jinan University, Zhuhai, 519000, Guangdong, China. lianghaihai@ems.hrbmu.edu.cn.ORCID http://orcid.org/0000-0003-4446-7035

Funding

National Natural Science Foundation of China U21A20339, 32171127
6 · The paper itself

Abstract

backgroundAberrant alternative splicing (AS) events, triggered by the alterations in serine/arginine splicing factor 1 (SRSF1), a member of the SR protein family, have been implicated in various pathological processes. However, the function and mechanism of SRSF1 in cardiovascular diseases remain unclear.

resultsIn this study, we found that the expression of SRSF1 was significantly down-regulated in the hearts of mice with acute myocardial infarction (AMI) and H9C2 cells exposed to H

conclusionsOur study unraveled the role of SRSF1 as a splicing factor involved in the regulation of Bcl2L12 splice switching, thereby exerting an anti-apoptotic effect through the p53 pathway, which provides new insights into potential approaches targeting cardiomyocyte apoptosis in cardiovascular diseases.

Indexed as

Alternative splicingApoptosisBcl2L12Myocardial infarctionSRSF1

Identifiers

PMID39578852
PMCPMC11585136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.